Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies-Reference-Cited by-同舟云学术

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Published:2021-01-03 Issue:7 Volume:100 Page:1863-1870
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Gordillo Christian A.,Parmar Sapna,Blanco Miranda,Delille Elsa M.,Assal Amer,Mapara Markus,Reshef Ran^ORCID

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04378-8.pdf

Reference19 articles.

1. Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, Hurd D, Forman W, Gordon EM, Coccia P (1983) Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359–367

2. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118:4346–4352

3. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin’s lymphoma. N Engl J Med 333:1995–1545

4. Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054

5. Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP (2008) High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 26:2240–2243

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m2 versus 140 mg/m2;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

3. The effect of breathing exercises on chemotherapy-induced nausea and vomiting in autologous hematopoietic stem cell transplantation patients: A randomized controlled trial;European Journal of Oncology Nursing;2024-06

4. Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants;Leukemia Research;2024-01

5. Design, synthesis and biological evaluation of novel cationic liposomes loaded with melphalan for the treatment of cancer;Bioorganic & Medicinal Chemistry Letters;2024-01